BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the irritable bowel syndrome (IBS) drug market, linaclotide (Ironwood/Forest/Almirall/Astellas’s Constella/Linzess), which launched on December 17th in the United States and received marketing authorization in Europe in November 2012, will capture significant market share from Sucampo/Takeda/Abbott’s Amitiza, owing to linaclotide’s superior efficacy in treating motility, as well as the drug’s demonstrated efficacy in addressing other important symptoms of IBS with constipation (IBS-C), including abdominal pain and bloating. In 2021, linaclotide will achieve blockbuster sales of $1.2 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
“This trend will contribute to the IBS market increasing to $3.2 billion in 2021.”
The upcoming Pharmacor advisory service entitled Irritable Bowel Syndrome, which will be published soon, also finds that despite the availability of over-the-counter (OTC) products (not included in Decision Resources’ IBS forecast)—which can be sufficient for patients with mild to moderate symptoms of IBS—the prescription IBS market is poised for significant growth through 2021, given the unmet need for more effective therapies for patients with moderate to severe disease, and the launch of novel therapies to treat subpopulations of IBS patients, notably IBS-C and IBS with diarrhea (IBS-D) patients.
“Although diagnosis and drug-treatment rates remain low across the major markets under study, given the availability of OTC products which can be effective for mild to moderate patients, we forecast that increasing awareness and diagnosis of the disease and the launch of high-priced emerging therapies targeting not only motility but also abdominal pain and bloating will result in an expanding prescription IBS market,” said Decision Resources Analyst Kathryn Beane. “This trend will contribute to the IBS market increasing to $3.2 billion in 2021.”
The findings also reveal that therapies with efficacy against abdominal pain remains an important unmet need for IBS, and several drugs forecast to launch through 2021—including Furiex Pharmaceuticals’ MuDelta, Tioga/Ono Pharmaceuticals’ asimadoline and Lexicon Pharmaceutical’s LX-1033—have shown efficacy against abdominal pain, albeit modest in some instances, in clinical trials. Four novel therapies are expected to launch in the United States, where sales of IBS therapies will increase the most rapidly and account for a large majority of the market in 2021.
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.